Collaboration agreement with Galapagos
MIMETAS and Galapagos to develop human disease models on-a-chip
MIMETAS and Galapagos will collaborate to develop miniaturized 3D cell culture models that mimic specific aspects of human diseases. These models will be applied to the identification and improvement of novel compounds. Dr. Richard Janssen, Senior Director of Target Discovery at Galapagos, states: “The MIMETAS platform is the first to combine organ-on-a-chip technology with our high throughput screening of primary human cells. As we see it, OrganoPlates® make 3D culture as straightforward as traditional cell culture.”
Dr. Jos Joore, MIMETAS’ CBO underscores this notion: “This agreement is a crucial step forward for MIMETAS and for the organ-on-a-chip field in general. Galapagos sets an example as one of the first drug discovery companies worldwide to implement innovative organ-on-a-chip technologies. This collaboration helps us to further validate our technology, by enabling development of unique novel compounds with unique human disease models.”
Financial and technological details of the agreement have not been disclosed.
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline comprising of six Phase 2 studies (three led by GSK), one Phase 1 study, five pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has around 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium. Further information at: www.glpg.com